Sweden's SciBase Q4 sales rise on US, skin barrier growth

SciBase Holding AB (publ)

13/03/2026 07:13

Overview

Sweden medical technology firm's Q4 net sales rose 45% yr/yr, loss after tax widened

Gross margin fell to 63% from 68.5%, impacted by currency and higher input costs

Outlook

Company did not provide specific financial or operational guidance for the future in its press release

Result Drivers

ELECTRODE SALES - Electrode sales volume rose 67% in Q4, with repeat sales to existing customers up 48%

GROSS MARGIN PRESSURE - Gross margin was negatively affected by currency, higher gold prices, initial delivery to Castle Biosciences, and increased production investments

US AND SKIN BARRIER GROWTH - US skin cancer sales rose 84% (106% in local currency), and skin barrier segment sales surged 294%

Company press release: ID:nWkr5bvdrp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 12.48 mln
Q4 EPS
-SEK 0.06
Q4 Net Income
-SEK 25.30 mln
Q4 Gross Margin
63.00%


Analyst Coverage

Wall Street's median 12-month price target for SciBase Holding AB (publ) is SEK0.50, about 79.9% above its March 12 closing price of SEK0.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)